| Literature DB >> 27996026 |
Yuqing Tang1, Chaojie Liu2, Xinping Zhang1.
Abstract
The overprovision and irrational use of antibiotics and injections are a major public health concern. Public reporting has been adopted as a strategy to encourage good prescribing practices. This study evaluated the effects of public reporting on antibiotic and injection prescriptions in urban and rural primary care settings in Hubei province, China. A randomized control trial was conducted, with 10 primary care institutions being subject to public reporting and another 10 serving as controls. Prescription indicators were publicly reported monthly over a one-year period. Prescriptions for bronchitis, gastritis and hypertension before and after the intervention were collected. Difference-in-difference tests were performed to estimate the effect size of the intervention on five prescription indicators: percentage of prescriptions containing antibiotics; percentage of prescriptions containing two or more antibiotics; percentage of prescriptions containing injections; percentage of prescriptions containing antibiotic injections; and average prescription cost. Public reporting had varied effects on prescriptions for different diagnoses. It reduced antibiotic prescribing for gastritis. Prescriptions containing injections, especially antibiotic injections, also declined, but only for gastritis. A reduction of prescription costs was noted for bronchitis and gastritis. Public reporting has the potential to encourage good prescribing practices. Its effects vary with different disease conditions.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27996026 PMCID: PMC5172199 DOI: 10.1038/srep39361
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Characteristics of recipients (patients) and prescribers (physicians) of prescriptions.
| Prescription | Bronchitis | Gastritis | Hypertension | |||
|---|---|---|---|---|---|---|
| Intervention | Control | Intervention | Control | Intervention | Control | |
| Age (years, mean ± SD) | 25.7 ± 24.9 | 32.2 ± 25.7 | 50.5 ± 18.5 | 49.0 ± 20.0 | 58.1 ± 15.2 | 58.5 ± 15.8 |
| Male (n, %) | 12269 (49.9) | 6044 (52.4) | 3189 (42.6) | 3330 (45.3) | 4932 (46.1) | 3756 (48.9) |
| NCMS coverage (n, %) | 21925 (89.2) | 10131 (87.8) | 6832 (91.2) | 6626 (90) | 10337 (96.7) | 7400 (96.3) |
| Age (years, mean ± SD) | 39.05 ± 8.25 | 43.42 ± 9.31 | 40.11 ± 8.58 | 43.41 ± 9.04 | 39.32 ± 8.30 | 43.28 ± 8.91 |
| Male (n, %) | 55 (74.32) | 58 (74.36) | 55 (75.34) | 62 (75.61) | 57 (73.08) | 60 (72.29) |
| 19 (25.68) | 29 (37.18) | 19 (26.03) | 29 (35.37) | 21 (26.92) | 31 (37.35) | |
| 44 (59.46) | 37 (47.44) | 41 (56.16) | 42 (51.22) | 44 (56.41) | 39 (46.99) | |
| 11 (14.86) | 12 (15.38) | 13 (17.81) | 11 (13.41) | 13 (16.67) | 13 (15.66) | |
| 21 (28.38) | 17 (21.79) | 20 (27.40) | 17 (20.73) | 26 (33.33) | 17 (20.48) | |
| 33 (44.59) | 14 (17.95) | 30 (41.10) | 15 (18.29) | 29 (37.18) | 16 (19.28) | |
| 18 (24.32) | 42 (53.85) | 20 (27.40) | 46 (56.10) | 19 (24.36) | 44 (53.01) | |
| 2 (2.70) | 5 (6.41) | 3 (4.11) | 4 (4.88) | 4 (5.13) | 6 (7.23) | |
| 17 (22.97) | 21 (26.92) | 16 (21.92) | 20 (24.39) | 15 (19.23) | 22 (26.51) | |
| 26 (35.14) | 25 (32.05) | 28 (38.36) | 28 (34.15) | 31 (39.74) | 26 (31.33) | |
| 16 (21.62) | 24 (30.77) | 16 (21.92) | 24 (29.27) | 18 (23.08) | 24 (28.92) | |
| 9 (12.16) | 5 (6.41) | 7 (9.59) | 7 (8.54) | 9 (11.54) | 8 (9.64) | |
| 6 (8.11) | 3 (3.85) | 6 (8.22) | 3 (3.66) | 5 (6.41) | 3 (3.61) | |
Note: NCMS – New Cooperative Medical Scheme.
Figure 1Monthly results of prescribing indicators over time.
To make a clearer view, the average cost of bronchitis were 10 minus on every single dot for both intervention and control groups.
Estimates of effect sizes derived from the difference-in-difference analyses.
| Intervention effect | 95%CI | Z | ||
|---|---|---|---|---|
| Bronchitis | 0.02% | [−0.9%, 0.09%] | 0.05 | 0.964 |
| Gastritis | [−16.59%, −8.85%] | −6.45 | < 0.001 | |
| Hypertension | [0.53%, 3.47%] | 2.67 | 0.008 | |
| Bronchitis | [−6.42%, −1.17%] | −2.83 | 0.005 | |
| Gastritis | −0.096% | [−1.56%, 1.37%] | −0.13 | 0.898 |
| Hypertension | 0.44% | [−0.041%, 0.91%] | 1.79 | 0.073 |
| Bronchitis | [0.43%, 3.56%] | 2.50 | 0.012 | |
| Gastritis | [−14.47%, -6.62%] | −5.22 | < 0.001 | |
| Hypertension | −0.97% | [−3.37%, 1.43%] | −0.79 | 0.428 |
| Bronchitis | −0.075% | [−2.02%, 1.87%] | −0.08 | 0.939 |
| Gastritis | [−14.41%, −7.04%] | −5.70 | < 0.001 | |
| Hypertension | −0.18% | [−0.80%, 0.44%] | −0.57 | 0.569 |
| Bronchitis | [−10.22%, −5.59%] | −6.69 | < 0.001 | |
| Gastritis | [−9.72%, −1.69%] | −2.79 | 0.005 | |
| Hypertension | −1.72% | [−5.61%, 2.18%] | −0.86 | 0.388 |
Note: CI - Confidence Interval.